Literature DB >> 18435801

Infiltration of forkhead box P3-expressing cells in small intestinal mucosa in coeliac disease but not in type 1 diabetes.

M Tiittanen1, M Westerholm-Ormio, M Verkasalo, E Savilahti, O Vaarala.   

Abstract

Because the role of regulatory T cells in the intestinal inflammation is unknown in coeliac disease (CD) and type 1 diabetes (T1D), the expression of forkhead box P3 (FoxP3), CD25, transforming growth factor-beta, interferon (IFN)-gamma, interleukin (IL)-4, IL-8, IL-10, IL-15 and IL-18 was measured by quantitative reverse transcription-polymerase chain reaction in the small intestinal biopsies from paediatric patients with active or potential CD, T1D and control patients. The numbers of FoxP3- and CD25-expressing cells were studied with immunohistochemistry. Enhanced intestinal expressions of FoxP3, IL-10 and IFN-gamma mRNAs were found in active CD when compared with controls (P-values < 0.001, 0.004, <0.001). In potential CD, only the expression of IFN-gamma mRNA was increased. The numbers of FoxP3-expressing cells were higher in active and potential CD (P < 0.001, P = 0.05), and the ratio of FoxP3 mRNA to the number of FoxP3-positive cells was decreased in potential CD when compared with controls (P = 0.007). The ratio of IFN-gamma to FoxP3-specific mRNA was increased in active and potential CD (P = 0.001 and P = 0.002). Patients with T1D had no changes in regulatory T cell markers, but showed increased expression of IL-18 mRNA. The impaired up-regulation of FoxP3 transcripts despite the infiltration of FoxP3-positive cells in potential CD may contribute to the persistence of inflammation. The increased ratio of IFN-gamma to FoxP3 mRNA in active and potential CD suggests an imbalance between regulatory and effector mechanisms. The increased intestinal expression of IL-18 mRNA in patients with T1D adds evidence in favour of the hypothesis that T1D is associated with derangements in the gut immune system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435801      PMCID: PMC2453216          DOI: 10.1111/j.1365-2249.2008.03662.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  A type 1 diabetes-related protein from wheat (Triticum aestivum). cDNA clone of a wheat storage globulin, Glb1, linked to islet damage.

Authors:  Amanda J MacFarlane; Karolina M Burghardt; John Kelly; Tuula Simell; Olli Simell; Illimar Altosaar; Fraser W Scott
Journal:  J Biol Chem       Date:  2002-10-29       Impact factor: 5.157

2.  Interleukin-18 promoter polymorphisms in type 1 diabetes.

Authors:  Adam Kretowski; Katarzyna Mironczuk; Anna Karpinska; Urszula Bojaryn; Maciej Kinalski; Zbigniew Puchalski; Ida Kinalska
Journal:  Diabetes       Date:  2002-11       Impact factor: 9.461

3.  Serum levels of the interferon-gamma-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes.

Authors:  F Nicoletti; I Conget; R Di Marco; A M Speciale; R Morìnigo; K Bendtzen; R Gomis
Journal:  Diabetologia       Date:  2001-03       Impact factor: 10.122

4.  Inflammatory cytokines in small intestinal mucosa of patients with potential coeliac disease.

Authors:  M Westerholm-Ormio; J Garioch; I Ketola; E Savilahti
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

5.  Interleukin 18 and associated markers of T helper cell type 1 activity in coeliac disease.

Authors:  V M Salvati; T T MacDonald; M Bajaj-Elliott; M Borrelli; A Staiano; S Auricchio; R Troncone; G Monteleone
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 6.  Screening for coeliac disease in type 1 diabetes.

Authors:  G K T Holmes
Journal:  Arch Dis Child       Date:  2002-12       Impact factor: 3.791

7.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.

Authors:  Jun Wang; Andreea Ioan-Facsinay; Ellen I H van der Voort; Tom W J Huizinga; René E M Toes
Journal:  Eur J Immunol       Date:  2007-01       Impact factor: 5.532

8.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

9.  Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease.

Authors:  Göte Forsberg; Olle Hernell; Silvia Melgar; Anne Israelsson; Sten Hammarström; Marie-Louise Hammarström
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

10.  Interleukin 15 mediates epithelial changes in celiac disease.

Authors:  L Maiuri; C Ciacci; S Auricchio; V Brown; S Quaratino; M Londei
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

View more
  35 in total

Review 1.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 2.  Effector and suppressor T cells in celiac disease.

Authors:  Giuseppe Mazzarella
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

Review 3.  Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease.

Authors:  M A Atkinson; A Chervonsky
Journal:  Diabetologia       Date:  2012-08-09       Impact factor: 10.122

Review 4.  Gut microbiota and type 1 diabetes.

Authors:  Outi Vaarala
Journal:  Rev Diabet Stud       Date:  2012-12-28

Review 5.  Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans.

Authors:  Dror S Shouval; Jodie Ouahed; Amlan Biswas; Jeremy A Goettel; Bruce H Horwitz; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

6.  Celiac disease in patients with type 1 diabetes: a condition with distinct changes in intestinal immunity?

Authors:  Raivo Uibo; Marina Panarina; Kaupo Teesalu; Ija Talja; Epp Sepp; Meeme Utt; Marika Mikelsaar; Kaire Heilman; Oivi Uibo; Tamara Vorobjova
Journal:  Cell Mol Immunol       Date:  2011-02-14       Impact factor: 11.530

7.  Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.

Authors:  Tiina Rauhavirta; Mikko Oittinen; Rami Kivistö; Pekka T Männistö; J Arturo Garcia-Horsman; Zhuo Wang; Martin Griffin; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  J Clin Immunol       Date:  2012-08-10       Impact factor: 8.317

8.  Fermentable fibres condition colon microbiota and promote diabetogenesis in NOD mice.

Authors:  Raine K Toivonen; Rohini Emani; Eveliina Munukka; Anniina Rintala; Asta Laiho; Sami Pietilä; Juha-Pekka Pursiheimo; Pasi Soidinsalo; Mari Linhala; Erkki Eerola; Pentti Huovinen; Arno Hänninen
Journal:  Diabetologia       Date:  2014-07-17       Impact factor: 10.122

9.  Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients.

Authors:  Marcela Medina; Giada De Palma; Carmen Ribes-Koninckx; Miguel Calabuig; Yolanda Sanz
Journal:  J Inflamm (Lond)       Date:  2008-11-03       Impact factor: 4.981

10.  Diabetes-specific HLA-DR-restricted proinflammatory T-cell response to wheat polypeptides in tissue transglutaminase antibody-negative patients with type 1 diabetes.

Authors:  Majid Mojibian; Habiba Chakir; David E Lefebvre; Jennifer A Crookshank; Brigitte Sonier; Erin Keely; Fraser W Scott
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.